Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Assessing chemotherapy and immunotherapy in dMMR endometrial cancer

Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, provides updates on Phase III trials evaluating chemotherapy and immunotherapy in patients with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) recurrent/metastatic endometrial cancer. Addition of immunotherapy to carboplatin and paclitaxel increases progression-free survival in this group of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.